JCR Pharmaceuticals Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Second Quarter of Fiscal Year 2019 and Year Ending March 31, 2019
The company also provided earnings guidance for the second quarter of fiscal year 2019 and year ending March 31, 2019. For the second quarter, the company expects net sales of JPY 9,400 million. Operating income is expected to be JPY 820 million. Ordinary income is expected to be JPY 870 million. Profit attributable to the owners of the parent is expected to be JPY 650 million. Net income per share is expected to be JPY 21.13 per share.
For the year, the company expects net sales of JPY 21,900 million. Operating income is expected to be JPY 4,290 million. Ordinary income is expected to be JPY 4,360 million. Profit attributable to the owners of the parent is expected to be JPY 3,200 million. Net income per share is expected to be JPY 104.05 per share.